Pharma companies directory 2026

Pharmaceutical Companies in Colombia

Colombia’s medicine business is an insurance business: almost every resident is assigned to an EPS, ADRES moves the UPC money, and ASCIF put 2024 market value near COP 29 trillion, with ninety-eight INVIMA-certified plants still supplying about four fifths of units used in the system.

INVIMA holds the sanitary registration and inspects those plants. The Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (CIR) then caps many molecules, so a launch model that worked in an unregulated Andean neighbour can fail on the first circular. Public and contributory demand is not a ministry warehouse; it is a chain of EPS plans that contract gestores farmacéuticos such as Audifarma, Cruz Verde and Colsubsidio, then wait on ADRES to replenish the UPC and the maximum budgets for high-cost care. When that chain stalls, laboratories collect 90- to 180-day receivables and some gestores enter reorganisation, which is why cash-cycle diligence sits next to clinical diligence in any Colombia plan. Constitutional tutelas still pull originator and orphan brands into treatment when the Plan de Beneficios omits them, creating a parallel high-cost channel that Roche, Novartis and Pfizer know well. On the industrial side, Procaps in Barranquilla and Tecnoquímicas in Cali give Colombia a genuine Andean manufacturing base, while Sanofi’s Genfar and Lafrancol brands sit on top of acquired Colombian houses. The accounts below are the makers, affiliates, gestores and public bodies BioNixus treats as the competitive set in Bogotá, Medellín and Cali.

Updated September 2026 · INVIMA — registros sanitarios and certified pharmaceutical establishments as of September 2026 · 19 named accounts

Request a proposal for Colombia Browse the 19 companies

COP 29tn

Pharmaceutical market in 2024, per ASCIF

INVIMA-certified pharmaceutical plants (ASCIF, 2025)

~80%

Share of medicines used, by volume, supplied by domestic manufacturers (ASCIF)

28–30%

Medicines as a share of the UPC health-insurance capitation (ASCIF)

Named accounts

Top pharmaceutical companies in Colombia

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against INVIMA — registros sanitarios and certified pharmaceutical establishments (as of 2026-09-04).

#	Company	HQ	Type	Therapeutic focus	Notes
01	INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos)	Bogotá	Government	Sanitary registration, GMP certification and market surveillance	The gate on every launch; backlog clearance and plant inspections in 2024–2026 have been as commercially important as any EPS listing.
02	ADRES (Administradora de los Recursos del Sistema General de Seguridad Social en Salud)	Bogotá	Government	UPC transfers and high-cost budget flows to EPS organisations	The national purse for the insurance system; when ADRES payments slow, EPS plans and then gestores delay laboratory invoices.
03	Ministerio de Salud y Protección Social	Bogotá	Government	Benefits plan, pharmaceutical policy and UPC-setting	Writes the Plan de Beneficios and the political arithmetic of the UPC, which decides whether a newly registered molecule is actually paid for.
04	Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (CIR)	Bogotá	Government	Maximum-price circulars for regulated medicines and devices	Price regulator whose circulars can erase a launch premium overnight and force Andean transfer-price reviews.
05	Procaps	Barranquilla	Local	Softgels, solids, consumer health and contract manufacturing for the Andes	NASDAQ-listed Barranquilla group that is the clearest Colombian example of a plant used as an Andean export platform, not only a domestic brand house.
06	Tecnoquímicas	Cali	Local	OTC, personal care, generics and mass-channel brands (including MK)	Cali-based private group that owns some of the most visible pharmacy brands in the country and a plant network built for volume, not specialty.
07	Laboratorio Franco Colombiano (Lafrancol)	Cali	MNC	Branded generics and established prescription lines inside Sanofi	Historic Colombian house acquired by Sanofi; the Lafrancol name still appears on packs and in EPS listings alongside Genfar.
08	Genfar (Sanofi)	Cali	MNC	Affordable generics for the EPS and private pharmacy channels	Sanofi’s Andean generics brand, built on a Colombian manufacturing base and used as the high-volume counterpart to Sanofi’s innovator book.
09	Sanofi Colombia	Bogotá	MNC	Vaccines, diabetes, rare disease and the Genfar / Lafrancol generics stack	The affiliate that now owns the two largest acquired Colombian generics identities and still details innovator specialties to hospital committees.
10	Pfizer Colombia	Bogotá	MNC	Vaccines, oncology, anti-infectives and hospital specialty	Innovator affiliate whose high-cost lines are frequent subjects of EPS maximum-budget fights and of tutelas when the benefits plan lags the label.
11	Novartis de Colombia	Bogotá	MNC	Cardiology, oncology, immunology and ophthalmology	Keeps a specialty model that depends on EPS high-cost pathways and judicial access as much as on INVIMA approval.
12	Roche Colombia	Bogotá	MNC	Oncology, neuroscience, ophthalmology and diagnostics	A regular party in tutela and maximum-budget cases for oncology biologics, with diagnostics pulling companion-test demand in private institutes.
13	Abbott Colombia	Bogotá	MNC	Established pharmaceuticals, nutrition and diagnostics	Broad affiliate whose nutrition and mature brands sit in both EPS dispensaries and private pharmacies, unlike pure oncology houses.
14	Laboratorios Chalver	Bogotá	Local	Generics and hospital products for institutional contracts	Domestic manufacturer that competes for EPS and hospital lots where CIR-capped molecules leave little room for brand premiums.
15	Humax Pharmaceutical	Medellín	Local	Branded generics and specialty hospital lines	Antioquia-based lab that shows up in Medellín institutional work and in Andean export registrations beyond the EPS channel.
16	Laboratorios Ecar	Medellín	Local	Primary-care generics and institutional tenders	Another Medellín manufacturer used as a price benchmark in EPS generic lots once CIR circulars have flattened originator mark-ups.
17	Adium Colombia (ex Biotoscana)	Bogotá	Regional	Specialty and licensed innovator brands across the Andes	Regional specialty group that in-licenses oncology and rare-disease products for Colombia when a global affiliate is thin or absent.
18	Audifarma	Pereira	Distributor	EPS pharmaceutical management and institutional dispensing	A leading gestor whose payment delays and 2020s reorganisation made it a credit-risk case study for every laboratory selling into the EPS channel.
19	Cruz Verde Colombia	Bogotá	Retailer	Pharmacy chain and EPS dispensing network	Retail and institutional hybrid: a consumer-facing chain that also dispenses for millions of EPS affiliates, so listing talks cover two P&Ls.

Primary research

These are the pharmaceutical companies accounts we study in Colombia

Need account-level or SKU-level data for a brand in Colombia? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Colombia?

Primary research, market access & HEOR. Proposals within 48 hours.

Top healthcare market research companies in Colombia (2026)

How the market is structured

How INVIMA, CIR, EPS plans and ADRES move a medicine

A product needs an INVIMA registro sanitario held by a Colombian establishment, plus GMP certification of the manufacturing site. Parallel to that file, the CIR publishes price-regulation circulars that set maximums for a long list of molecules; companies therefore model both the INVIMA clock and the circular that will cap the ex-manufacturer price. Once registered, most volume does not go to a ministry tender. EPS organisations in the contributory and subsidised regimes contract pharmacies and gestores to dispense the Plan de Beneficios, and ADRES pays the UPC plus, for many high-cost technologies, maximum budgets that have been politically contested. Specialised and oncologic lines often travel through those maximum-budget rules or through tutelas ordered by judges under Article 86 of the Constitution, which is why access for a new biologic can look like a legal caseload as much as a formulary win. Institutional gestores — Audifarma, Cruz Verde, Colsubsidio, Cafam — concentrate dispensing for tens of millions of affiliates and have become the credit counterpart that laboratories actually invoice. Retail OTC and private prescription volume, by contrast, still runs through Tecnoquímicas-style consumer brands and through independent droguerías and chain pharmacies that patients pay out of pocket. Andean export manufacturing, especially Procaps softgels and solids shipped from Barranquilla, sits beside this domestic insurance machine and is one reason Colombia is used as a regional supply point rather than only as a demand market.

Local

Colombian manufacturers in Barranquilla, Cali, Medellín and Bogotá that still supply most units used in the EPS system and, in Procaps’ case, run Andean export plants.

Procaps
Tecnoquímicas
Laboratorios Chalver
Humax Pharmaceutical
Laboratorios Ecar

Multinational

Innovator affiliates plus Sanofi’s acquired Colombian generics brands, selling into EPS high-cost pathways, tutelas and private institutes.

Laboratorio Franco Colombiano (Lafrancol)
Genfar (Sanofi)
Sanofi Colombia
Pfizer Colombia
Novartis de Colombia
Roche Colombia
Abbott Colombia

Regional

Andean specialty groups such as Adium that in-license molecules for Colombia rather than building a full primary-care field force.

Adium Colombia (ex Biotoscana)

Distributors & importers

EPS gestores, Cruz Verde and the public bodies — INVIMA, CIR, ADRES, the Ministry — whose circulars, UPC flows and invoices define cash conversion.

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos)
ADRES (Administradora de los Recursos del Sistema General de Seguridad Social en Salud)
Ministerio de Salud y Protección Social
Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos (CIR)
Audifarma
Cruz Verde Colombia

What is moving

What is moving the pharmaceutical market in Colombia

EPS and ADRES liquidity stress

Stretched UPC arithmetic and gestor arrears are forcing laboratories to ration institutional credit and to prefer cash retail or export plants over EPS-only launches.

CIR price circulars on originator premiums

Maximum-price regulation keeps pulling high-visibility molecules toward generic and biosimilar bids, which favours Genfar, Chalver, Ecar and other volume manufacturers.

Tutela-driven high-cost access

Judicial orders continue to open treatment for oncology and orphan brands omitted from the benefits plan, creating a caseload channel that specialty affiliates must staff.

Andean manufacturing from Barranquilla and Cali

Procaps and Tecnoquímicas plants, plus Sanofi’s inherited Colombian sites, let companies use Colombia as a supply hub for Central America and the Andes rather than only as a demand market.

INVIMA backlog clearance

Agency efforts to work through pending sanitary registrations change launch sequencing: a file that sat for years can suddenly compete with an already-detailed brand.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Colombia

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Colombia:

EPS medical-director and gestor credit interviews in Bogotá mapping UPC shortfalls, maximum-budget disputes and laboratory receivable days.
Oncology and high-cost committee discussions in Bogotá, Medellín and Cali on tutela caseloads versus benefits-plan listings for the same molecule.
CIR circular impact reviews: pre- and post-regulation ex-manufacturer prices for a basket of originator and generic molecules.
Andean plant and export interviews at Barranquilla and Cali sites, including Procaps contract-manufacturing capacity and Tecnoquímicas OTC lines.

Questions

Frequently Asked Questions

Which laboratories actually make medicines in Colombia?

Procaps, Tecnoquímicas, the Sanofi-owned Genfar and Lafrancol sites, Chalver, Humax and Ecar are the names that recur on INVIMA plant lists. ASCIF counted 98 certified plants and said domestic makers still supply about four fifths of units. Innovator affiliates import most of their specialty book.

How does INVIMA registration interact with CIR prices?

INVIMA decides whether the product may be sold; CIR circulars then often cap what may be charged. A clean sanitary file with an unworkable maximum price is a common reason specialty teams pause a Colombia launch after approval.

Who pays for medicines inside the EPS system?

EPS plans contract gestores and pharmacies to dispense the benefits plan. ADRES funds those plans through the UPC and through maximum budgets for many high-cost technologies. Laboratories invoice the gestor or the EPS, not ADRES directly, which is why gestor liquidity has become a credit topic.

What is a tutela and why do specialty brands care?

A constitutional injunction (Article 86) that a patient can use to obtain a medicine the benefits plan does not cover. Oncology and orphan brands at Roche, Novartis and Pfizer still see a material slice of treated patients arrive through this judicial door.

How does BioNixus study the Colombian pharmaceutical industry on the ground?

EPS and gestor credit interviews in Bogotá; hospital and oncology-committee work in Bogotá, Medellín and Cali; CIR circular impact reviews by molecule; and plant tours at Barranquilla and Cali sites used for Andean supply.

Should readers treat this Colombia list as a sales ranking?

No. The directory is a map of INVIMA-licensed makers, EPS-facing institutions and Andean plants that BioNixus meets in fieldwork. Order is editorial, not a league table of revenue.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Colombia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: INVIMA — registros sanitarios and certified pharmaceutical establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Colombia, not size.

ASCIF / PharmaBoardroom interview with Clara Rodríguez on 2024 market value (COP 29 trillion), plant count and domestic volume share, 2025
La República and Portafolio coverage of EPS / gestor arrears and Audifarma reorganisation, 2024–2025
Ministry of Health and CIR circulars on medicine price regulation; ADRES UPC and maximum-budget rules
BioNixus Colombia EPS, hospital and manufacturing fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Colombia?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Colombia?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Colombia

Top pharmaceutical companies in Colombia

These are the pharmaceutical companies accounts we study in Colombia

Planning research in Colombia?

How INVIMA, CIR, EPS plans and ADRES move a medicine

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Colombia

EPS and ADRES liquidity stress

CIR price circulars on originator premiums

Tutela-driven high-cost access

Andean manufacturing from Barranquilla and Cali

INVIMA backlog clearance

How BioNixus studies pharmaceutical companies in Colombia

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Colombia?

Planning research in Colombia?